Skip to main content
PMC home page
Journal of Epidemiology and Community Health logoLink to Journal of Epidemiology and Community Health
. 2004 Nov;58(11):944–950. doi: 10.1136/jech.2003.017475

Gender differences in progression to AIDS and death from HIV seroconversion in a cohort of injecting dug users from 1986 to 2001

M G de la Hera 1, I Ferreros 1, J del Amo 1, P G de Olalla 1, S P Hoyos 1, R Muga 1, J del Romero 1, R Guerrero 1, I Hernandez-Aguado 1, G and 1
PMCID: PMC1732603  PMID: 15483312

Abstract

Background: Although the consensus is that gender does not influence HIV progression, its relevance may depend on the setting.

Aim: To study gender differences in HIV progression to AIDS and death from 1986 to 2001 in a cohort of injecting drug user (IDU) seroconverters in Spain.

Methods: Risk of AIDS and death in persons infected for the same length of time were compared through Kaplan-Meier, allowing for late entry, and Cox regression adjusting for gender, age, and calendar period (before 1992, 1992–1995, 1996–1998, 1999–2001) fitted as time dependent covariates.

Results: Of 929 IDU, 24.7% were women. Median seroconversion year was 1993.3 for men and women. 44% of women and 34% of men received antiretroviral therapy. Risk of AIDS was lower in women in univariate (hazard ratio (HR) 0.72; 95%CI:0.51 to 1.01) and multivariate analyses (HR 0.73 95%CI:0.52 to 1.03). A 46% reduction in risk of AIDS for period 1999–2001 compared with 1992–1995 was seen in both men and women (HR: 0.56 (95%CI:0.36 to 0.87). As for mortality, women's risk of death was lower univariately (HR 0.67 95%CI:0.45 to 0.99) although compared with 1992–95, men experienced a 34% reduction in mortality during 1999–2001 (HR 0.66 95%CI:0.40 to 1.01), which was not statistically significant in women.

Conclusions: HIV progression was lower in female IDU before and after 1997 and their uptake of antiretroviral therapy was higher than male IDU. The inability to detect a reduction in mortality for women during 1999–2001 is probably attributable to lack of power. Differences in severity of addiction, drug using patterns, and competing causes of death may explain these findings.

Full Text

The Full Text of this article is available as a PDF (149.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ajdacic-Gross V., Zellweger U., Wang J., Fleerackers Y., Somaini B. How complete is AIDS surveillance in Europe? An eagle eye comparison with mortality data. J Epidemiol Community Health. 2001 Jan;55(1):52–56. doi: 10.1136/jech.55.1.52. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Barrasa A., Castilla J., Pereira J., Herrera D., Martínez-Navarro F. Exhaustividad de los registros de sida en España. Gac Sanit. 2001 Nov-Dec;15(6):482–489. doi: 10.1016/s0213-9111(01)71610-x. [DOI] [PubMed] [Google Scholar]
  3. Castilla J., Martínez de Aragón M. V., Gutiérrez A., Llácer A., Belza M. J., Ruiz C., Pérez de la Paz J., Noguer I. Impact of human immunodeficiency virus infection on mortality among young men and women in Spain. Int J Epidemiol. 1997 Dec;26(6):1346–1351. doi: 10.1093/ije/26.6.1346. [DOI] [PubMed] [Google Scholar]
  4. Cohen Mardge H., French Audrey L., Benning Lorie, Kovacs Andrea, Anastos Kathryn, Young Mary, Minkoff Howard, Hessol Nancy A. Causes of death among women with human immunodeficiency virus infection in the era of combination antiretroviral therapy. Am J Med. 2002 Aug 1;113(2):91–98. doi: 10.1016/s0002-9343(02)01169-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cozzi Lepri A., Pezzotti P., Dorrucci M., Phillips A. N., Rezza G. HIV disease progression in 854 women and men infected through injecting drug use and heterosexual sex and followed for up to nine years from seroconversion. Italian Seroconversion Study. BMJ. 1994 Dec 10;309(6968):1537–1542. doi: 10.1136/bmj.309.6968.1537. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Davies A. G., Dominy N. J., Peters A. D., Richardson A. M. Gender differences in HIV risk behaviour of injecting drug users in Edinburgh. AIDS Care. 1996 Oct;8(5):517–527. doi: 10.1080/09540129650125489. [DOI] [PubMed] [Google Scholar]
  7. Detels R., Muñoz A., McFarlane G., Kingsley L. A., Margolick J. B., Giorgi J., Schrager L. K., Phair J. P. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA. 1998 Nov 4;280(17):1497–1503. doi: 10.1001/jama.280.17.1497. [DOI] [PubMed] [Google Scholar]
  8. Dorrucci M., Balducci M., Pezzotti P., Sinicco A., Alberici F., Rezza G. Temporal changes in the rate of progression to death among Italians with known date of HIV seroconversion: estimates of the population effect of treatment. Italian HIV Seroconversion Study (ISS). J Acquir Immune Defic Syndr. 1999 Sep 1;22(1):65–70. doi: 10.1097/00042560-199909010-00008. [DOI] [PubMed] [Google Scholar]
  9. Dray-Spira Rosemary, Lert France. Social health inequalities during the course of chronic HIV disease in the era of highly active antiretroviral therapy. AIDS. 2003 Feb 14;17(3):283–290. doi: 10.1097/00002030-200302140-00001. [DOI] [PubMed] [Google Scholar]
  10. Evans Jennifer L., Hahn Judith A., Page-Shafer Kimberly, Lum Paula J., Stein Ellen S., Davidson Peter J., Moss Andrew R. Gender differences in sexual and injection risk behavior among active young injection drug users in San Francisco (the UFO Study). J Urban Health. 2003 Mar;80(1):137–146. doi: 10.1093/jurban/jtg137. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Farzadegan H., Hoover D. R., Astemborski J., Lyles C. M., Margolick J. B., Markham R. B., Quinn T. C., Vlahov D. Sex differences in HIV-1 viral load and progression to AIDS. Lancet. 1998 Nov 7;352(9139):1510–1514. doi: 10.1016/S0140-6736(98)02372-1. [DOI] [PubMed] [Google Scholar]
  12. Gandhi Monica, Bacchetti Peter, Miotti Paolo, Quinn Thomas C., Veronese Fulvia, Greenblatt Ruth M. Does patient sex affect human immunodeficiency virus levels? Clin Infect Dis. 2002 Jul 2;35(3):313–322. doi: 10.1086/341249. [DOI] [PubMed] [Google Scholar]
  13. Gange S. J., Barrón Y., Greenblatt R. M., Anastos K., Minkoff H., Young M., Kovacs A., Cohen M., Meyer W. A., 3rd, Muñoz A. Effectiveness of highly active antiretroviral therapy among HIV-1 infected women. J Epidemiol Community Health. 2002 Feb;56(2):153–159. doi: 10.1136/jech.56.2.153. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. García de la Hera Manuela, Ruiz Isabel, Pérez-Hoyos Santiago, Hernández Aguado Ildefonso. Utilización de servicios sanitarios según el sexo en una cohorte de usuarios de drogas por vía parenteral infectados por el virus de la inmunodeficiencia humana. Med Clin (Barc) 2003 Apr 12;120(13):489–493. [PubMed] [Google Scholar]
  15. Hernández-Aguado I., Aviño M. J., Pérez-Hoyos S., González-Aracil J., Ruiz-Pérez I., Torrella A., García de la Hera M., Belda F., Fernández E., Santos C. Human immunodeficiency virus (HIV) infection in parenteral drug users: evolution of the epidemic over 10 years. Valencian Epidemiology and Prevention of HIV Disease Study Group. Int J Epidemiol. 1999 Apr;28(2):335–340. doi: 10.1093/ije/28.2.335. [DOI] [PubMed] [Google Scholar]
  16. Hogg R. S., Yip B., Chan K. J., Wood E., Craib K. J., O'Shaughnessy M. V., Montaner J. S. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA. 2001 Nov 28;286(20):2568–2577. doi: 10.1001/jama.286.20.2568. [DOI] [PubMed] [Google Scholar]
  17. Koppel K., Bratt G., Rajs J. Sudden cardiac death in a patient on 2 years of highly active antiretroviral treatment: a case report. AIDS. 1999 Oct 1;13(14):1993–1994. doi: 10.1097/00002030-199910010-00033. [DOI] [PubMed] [Google Scholar]
  18. Melnick S. L., Sherer R., Louis T. A., Hillman D., Rodriguez E. M., Lackman C., Capps L., Brown L. S., Jr, Carlyn M., Korvick J. A. Survival and disease progression according to gender of patients with HIV infection. The Terry Beirn Community Programs for Clinical Research on AIDS. JAMA. 1994 Dec 28;272(24):1915–1921. [PubMed] [Google Scholar]
  19. Mocroft A., Brettle R., Kirk O., Blaxhult A., Parkin J. M., Antunes F., Francioli P., D'Arminio Monforte A., Fox Z., Lundgren J. D. Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. AIDS. 2002 Aug 16;16(12):1663–1671. doi: 10.1097/00002030-200208160-00012. [DOI] [PubMed] [Google Scholar]
  20. Mocroft A., Vella S., Benfield T. L., Chiesi A., Miller V., Gargalianos P., d'Arminio Monforte A., Yust I., Bruun J. N., Phillips A. N. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet. 1998 Nov 28;352(9142):1725–1730. doi: 10.1016/s0140-6736(98)03201-2. [DOI] [PubMed] [Google Scholar]
  21. Moore Antonia L., Sabin Caroline A., Johnson Margaret A., Phillips Andrew N. Gender and clinical outcomes after starting highly active antiretroviral treatment: a cohort study. J Acquir Immune Defic Syndr. 2002 Feb 1;29(2):197–202. doi: 10.1097/00042560-200202010-00015. [DOI] [PubMed] [Google Scholar]
  22. Muga R., Egea J. M., Navío M., Sirera G., Vall M., Tor J. Mortalidad en una cohorte de usuarios de drogas por vía intravenosa antes de la introducción de la terapia VIH potente. Med Clin (Barc) 1999 May 29;112(19):721–725. [PubMed] [Google Scholar]
  23. Muga R., Roca J., Egea J. M., Tor J., Sirera G., Rey-Joly C., Muñoz A. Mortality of HIV-positive and HIV-negative heroin abusers as a function of duration of injecting drug use. J Acquir Immune Defic Syndr. 2000 Apr 1;23(4):332–338. doi: 10.1097/00126334-200004010-00009. [DOI] [PubMed] [Google Scholar]
  24. Muñoz A., Gange S. J., Jacobson L. P. Distinguishing efficacy, individual effectiveness and population effectiveness of therapies. AIDS. 2000 Apr 14;14(6):754–756. doi: 10.1097/00002030-200004140-00020. [DOI] [PubMed] [Google Scholar]
  25. Napravnik Sonia, Poole Charles, Thomas James C., Eron Joseph J., Jr Gender difference in HIV RNA levels: a meta-analysis of published studies. J Acquir Immune Defic Syndr. 2002 Sep 1;31(1):11–19. doi: 10.1097/00126334-200209010-00002. [DOI] [PubMed] [Google Scholar]
  26. Palella F. J., Jr, Delaney K. M., Moorman A. C., Loveless M. O., Fuhrer J., Satten G. A., Aschman D. J., Holmberg S. D. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998 Mar 26;338(13):853–860. doi: 10.1056/NEJM199803263381301. [DOI] [PubMed] [Google Scholar]
  27. Prins M., Hernández Aguado I. H., Brettle R. P., Robertson J. R., Broers B., Carré N., Goldberg D. J., Zangerle R., Coutinho R. A., van den Hoek A. Pre-AIDS mortality from natural causes associated with HIV disease progression: evidence from the European Seroconverter Study among injecting drug users. AIDS. 1997 Nov 15;11(14):1747–1756. doi: 10.1097/00002030-199714000-00012. [DOI] [PubMed] [Google Scholar]
  28. Prins M., Robertson J. R., Brettle R. P., Aguado I. H., Broers B., Boufassa F., Goldberg D. J., Zangerle R., Coutinho R. A., van den Hoek A. Do gender differences in CD4 cell counts matter? AIDS. 1999 Dec 3;13(17):2361–2364. doi: 10.1097/00002030-199912030-00007. [DOI] [PubMed] [Google Scholar]
  29. Pérez-Hoyos S., Ferreros I., del Amo J., Quintana M., Ruiz I., Cisneros J. M., Muga R., García de la Hera M., del Romero J., García de Olalla P. Imputación del instante de seroconversión al VIH en cohortes de hemofílicos. Gac Sanit. 2003 Nov-Dec;17(6):474–482. doi: 10.1016/s0213-9111(03)71794-4. [DOI] [PubMed] [Google Scholar]
  30. Sterling T. R., Vlahov D., Astemborski J., Hoover D. R., Margolick J. B., Quinn T. C. Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. N Engl J Med. 2001 Mar 8;344(10):720–725. doi: 10.1056/NEJM200103083441003. [DOI] [PubMed] [Google Scholar]
  31. Suligoi B. The natural history of human immunodeficiency virus infection among women as compared with men. Sex Transm Dis. 1997 Feb;24(2):77–83. doi: 10.1097/00007435-199702000-00004. [DOI] [PubMed] [Google Scholar]
  32. Tarwater P. M., Mellors J., Gore M. E., Margolick J. B., Phair J., Detels R., Muñoz A. Methods to assess population effectiveness of therapies in human immunodeficiency virus incident and prevalent cohorts. Am J Epidemiol. 2001 Oct 1;154(7):675–681. doi: 10.1093/aje/154.7.675. [DOI] [PubMed] [Google Scholar]
  33. Webber M. P., Schoenbaum E. E., Gourevitch M. N., Buono D., Klein R. S. A prospective study of HIV disease progression in female and male drug users. AIDS. 1999 Feb 4;13(2):257–262. doi: 10.1097/00002030-199902040-00014. [DOI] [PubMed] [Google Scholar]
  34. del Amo J., del Romero J., Barrasa A., Pérez-Hoyos S., Rodríguez C., Díez M., García S., Soriano V., Castilla J., Grupo de Seroconvertores de la Comunidad de Madrid Factors influencing HIV progression in a seroconverter cohort in Madrid from 1985 to 1999. Sex Transm Infect. 2002 Aug;78(4):255–260. doi: 10.1136/sti.78.4.255. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Epidemiology and Community Health are provided here courtesy of BMJ Publishing Group

RESOURCES